Semaglutide Injection Sites: Where and How

The labeled semaglutide injection sites are the same across the FDA-approved semaglutide pens: the abdomen, the front of the thigh, and the back of the upper arm, each given as a subcutaneous (under-the-skin) injection. The Wegovy prescribing information states verbatim, “Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification” (Wegovy FDA Prescribing Information). The Ozempic label lists the same three regions. This guide explains where and how, but it is educational only; your provider and the product’s Instructions for Use (IFU) are the authority on your specific situation.

Where are the semaglutide injection sites?

According to the FDA-approved labels, there are three subcutaneous regions for semaglutide. The Wegovy label and the Ozempic prescribing information (DailyMed) both specify the abdomen, the thigh, and the upper arm.

Site	Where, per official IFU guidance	Practical note
Abdomen (lower stomach)	Keep at least about 2 inches (roughly 5 cm) away from the navel/belly button	Often the easiest area to reach and pinch
Thigh (front of the upper leg)	Front of the thigh, per the official Wegovy pen guide	Easy to self-administer while seated
Upper arm (back of)	Back of the upper arm	Per the IFU, typically used only if someone else gives the injection, since most people cannot reach it themselves

The 2-inch-from-the-navel detail and the “front of the thigh” and “back of the upper arm” phrasing come from the official Wegovy patient pen guide. Treat these as IFU-derived pointers, not personalized instructions; the exact technique you should use is the one in your product’s IFU. If you are comparing semaglutide with the other major GLP-1 medication, our overview of tirzepatide vs. semaglutide covers how they differ, and where to inject tirzepatide walks through that drug’s labeled sites.

Can the injection site be changed without changing the dose?

Yes. The Wegovy label is explicit that “the time of day and the injection site can be changed without the need for a dosage modification” (Wegovy FDA Prescribing Information). The Ozempic label similarly notes that the injection site can be changed without a dose adjustment. In other words, switching among the abdomen, thigh, and upper arm does not, on its own, require any change to the prescribed dose. Even so, only your prescriber should decide your dose and any dose changes; this article does not provide dosing advice.

How do you rotate semaglutide injection sites?

Official guidance is to spread injections out rather than reuse one exact spot. The Wegovy pen guide states, “You may inject into the same body area each week, but not in the exact same spot each time.” The Ozempic label echoes this, directing patients to “use a different injection site each week when injecting in the same body region.” So you can keep using, say, your abdomen, but you should move to a slightly different point within that area each time.

This matches the broader GLP-1 pattern: the Mounjaro (tirzepatide) label instructs patients to “rotate injection sites with each dose” (Mounjaro FDA label, DailyMed — a tirzepatide source, included only for cross-drug consistency). For a sibling walk-through of the mechanics, see how to inject semaglutide.

What should you avoid when choosing a spot?

Per the official Wegovy patient guidance: “Do not inject into an area where the skin is tender, bruised, red, or hard.” It also advises avoiding scars and stretch marks. Choosing healthy, intact skin is part of why rotation matters. If you have any uncertainty about whether a particular area is suitable, your provider or pharmacist can advise, and the IFU is the definitive reference for your pen.

• Skin that is tender, bruised, red, or hard
• Scars and stretch marks
• The area right around the navel (stay about 2 inches away)
• The exact same spot used last time

What dose is in the pen, and how does it escalate?

Semaglutide is started low and increased gradually. Per the Wegovy label (Table 1), the once-weekly escalation is 0.25 mg, then 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg (or 1.7 mg), in roughly 4-week steps; if a dose is not tolerated, escalation may be delayed about 4 weeks. Ozempic, used for type 2 diabetes, initiates at 0.25 mg once weekly for 4 weeks (a starting dose that is not effective for glycemic control), then 0.5 mg, with possible increases to 1 mg and a maximum of 2 mg (Ozempic Prescribing Information).

Semaglutide product	Starting dose	Escalation	Maintenance / max
Wegovy (chronic weight management)	0.25 mg once weekly	0.25 → 0.5 → 1 → 1.7 → 2.4 mg, ~4-week steps	2.4 mg (or 1.7 mg)
Ozempic (type 2 diabetes)	0.25 mg once weekly (initiation only)	0.25 → 0.5 → 1 mg	Up to a maximum of 2 mg

These figures are label information, not a dosing instruction; your prescriber determines your schedule. For a deeper look at the numbers, see our semaglutide dosing chart.

How much weight did semaglutide produce in trials?

In the STEP 1 trial, once-weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention produced a mean body-weight change of about -14.9% from baseline at week 68, versus -2.4% with placebo (treatment policy estimand), in 1,961 adults without diabetes who had a BMI of 30 or higher (or 27 or higher with a weight-related condition) (Wilding et al., NEJM 2021). Both arms used a reduced-calorie diet and increased physical activity. This is a trial average; individual results vary, and outcomes are determined by your provider.

For context, a different drug, tirzepatide, was studied in SURMOUNT-1 (Jastreboff et al., NEJM 2022), with mean reductions of about 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses (treatment-regimen estimand) versus 3.1% placebo at 72 weeks, also with a reduced-calorie diet and increased physical activity. Those numbers are tirzepatide, not semaglutide, and should never be attributed to semaglutide. They appear here only to clearly label the GLP-1 contrast.

What about compounded semaglutide?

Wegovy and Ozempic (semaglutide) are FDA-approved. Compounded semaglutide is not FDA-approved; the FDA notes that unapproved versions “do not undergo FDA’s review for safety, effectiveness and quality before they are marketed,” and their active ingredients are often not FDA-evaluated or inspected (FDA: Concerns with Unapproved GLP-1 Drugs). Supply has also normalized: the FDA removed tirzepatide from its shortage list on October 2, 2024 (re-confirmed December 19, 2024) and marked semaglutide resolved on February 21, 2025. With the shortages resolved, the FDA’s temporary enforcement discretion for mass compounding of these GLP-1 copies has ended, so they may no longer be mass-produced by compounders (FDA compounding policy update). If you are weighing options, a licensed provider can explain what is appropriate for you.

Frequently asked questions

Where do you inject semaglutide?

Per the FDA-approved Wegovy and Ozempic labels, semaglutide is injected subcutaneously into the abdomen, the front of the thigh, or the back of the upper arm. Follow your product’s Instructions for Use and your prescriber’s guidance for technique.

Can I switch sites between injections?

Yes. The Wegovy label states the injection site can be changed without a dosage modification, and patients are told to rotate, using the same body area is fine but not the exact same spot each time. Your dose is set by your prescriber, not by which site you choose.

How far from the belly button should I inject in the abdomen?

The official Wegovy pen guidance says to keep at least about 2 inches (roughly 5 cm) away from the navel when injecting into the lower stomach. Refer to your IFU for the exact instruction.

What areas should I avoid?

Official Wegovy guidance says not to inject into skin that is tender, bruised, red, or hard, and to avoid scars and stretch marks. Choose healthy, intact skin and rotate spots within the area.

Why is the upper arm harder to use?

The labeled site is the back of the upper arm, which most people cannot reach themselves. Per the IFU, that site is typically used only when another trained person gives the injection.

Is this dosing advice?

No. This article is educational only. Site selection, technique, and dosing are determined by a licensed provider and the specific product IFU. Do not start, change, or self-manage a dose based on this page.